Live Breaking News & Updates on Biocity biopharma

Stay informed with the latest breaking news from Biocity biopharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Biocity biopharma and stay connected to the pulse of your community

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

/PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND)...

Yong-jiang , Zhejiang , China , Shanghai , Biocity-adcs , Prnewswire-biocity-biopharma , Linkedin-biocity-biopharma , Biocity-biopharma , Drug-administration , City-biopharma , Investigational-new-drug , Yong-jiang-hei

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Oregon , United-states , Hong-kong , United-kingdom , Switzerland , Texas , Swiss , American , Haihe-biopharma , Biocity-biopharma , Calithera-biosciences , Terremoto-biosciences

BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

/PRNewswire/ -- BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb)...

Zhongshan , Anhui , China , Chinese , Biocity-biopharma , Jia-fan , Prnewswire-biocity-biopharma , Astrazeneca , Chinese-academy-of-sciences , City-biopharma , Zhongshan-hospital , Chinese-academy

Contrasting GSK (NYSE:GSK) & AstraZeneca (OTCMKTS:AZNCF)

Contrasting GSK (NYSE:GSK) & AstraZeneca (OTCMKTS:AZNCF)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , United-states , Brentford , Hounslow , Cambridge , Cambridgeshire , Xigduo , Bricanyl-respules , Farxiga-forxiga , Duaklir-genuair , Daliresp-daxas , Biocity-biopharma

Riding the tide, realize the future: The BD paths for Chinese Biotech

Riding the tide, realize the future: The BD paths for Chinese Biotech
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Germany , Japan , Yong-jiang , Zhejiang , Chinese , Biocity-biopharmaceutics , Ivy-wang , Bristol-myer-squibb , Kaan-certel , Biocity-biopharma , Xiang-bo-jia

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody

/PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND)...

China , United-states , Biocity-biopharma , Prnewswire-biocity-biopharma , Drug-administration , City-biopharma , Investigational-new-drug ,

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial

BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Prnewswire-biocity-biopharma , Biocity-biopharma , City-biopharma ,

BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease

/PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent...

China , Yong-jiang , Zhejiang , Prnewswire-biocity-biopharma , Biocity-biopharma , City-biopharma , Yong-jiang-hei ,